Last quarter (Q4 2023), Innate Pharma S.A.'s total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Innate Pharma S.A.'s net income was $―. See Innate Pharma S.A.’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Total Revenue	$ ―	$ 61.64M	$ 57.67M	$ 24.70M	$ 69.77M	$ 85.45M
Cost of Revenue	$ ―	$ ―	$ -115.10M	$ 4.00M	$ -68.69M	$ -104.65M
Gross Profit	$ ―	$ 61.64M	$ 57.62M	$ 20.71M	$ 63.01M	$ 85.81M
Operating Expense	$ ―	$ 74.31M	$ 74.10M	$ 72.53M	$ 68.69M	$ 117.84M
Operating Income	$ ―	$ -12.67M	$ -16.48M	$ -51.82M	$ -5.68M	$ -32.03M
Net Non Operating Interest Income Expense	$ ―	$ 2.99M	$ 4.78M	$ 6.34M	$ 4.86M	$ 11.27M
Other Income Expense	$ ―	$ ―	$ -59.00K	$ -28.70M	$ -1.36M	$ -13.90M
Pretax Income	$ ―	$ -7.57M	$ -57.97M	$ -45.48M	$ -829.00K	$ 7.87M
Tax Provision	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Earnings From Equity Interest Net Of Tax	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ ―	$ -7.57M	$ -58.10M	$ -52.81M	$ -63.98M	$ -20.76M
Basic EPS	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Diluted EPS	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Basic Average Shares	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Diluted Average Shares	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Dividend Per Share	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ ―	$ 74.31M	$ -41.00M	$ 76.53M	$ -44.39M	$ 13.20M
Net Income From Continuing And Discontinued Operation	$ ―	$ -7.57M	$ -58.10M	$ -52.81M	$ -63.98M	$ -20.76M
Normalized Income	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
Interest Expense	$ ―	$ ―	$ ―	$ ―	$ ―	$ ―
EBIT	$ ―	$ ―	$ -58.26M	$ -45.48M	$ -64.33M	$ 7.66M
EBITDA	$ ―	$ ―	$ -12.86M	$ -40.88M	$ -7.53M	$ 24.19M

Currency in USD

Innate Pharma S.A. Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing